Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18240/ijo.2016.03.25 http://scihub22266oqcxt.onion/10.18240/ijo.2016.03.25 C4844053!4844053!27158622     free     free     free       Int+J+Ophthalmol 2016 ; 9 (3): 465-8 Nephropedia Template TP {{tp|p=27158622|t=2016. Mitomycin C in pterygium treatment |pdf=|usr=}}{{27158622}} gab.com Text Mitomycin C in pterygium treatment JO: Int J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=27158622 #FOAvip Pterygium is a benign lesion usually growing from the nasal side of the conjunctiva onto the cornea. Most cases of pterygium does not cause problem or requires specific treatment. The exact cause of pterygium is not clear yet, but some factors are pointed as causes, being the most important the long-term ultraviolet ray exposure. Pterygium surgery is usually considered when there are symptoms that do not respond to conservative treatment. Recurrence is the main complication of the surgery, and much has been done to avoid it. Mitomycin C (MMC) has been used as a fibroblast proliferation inhibitor during the surgery to reduce the chance of recurrence of the pterygium. This review describes the use of MMC as an adjunctive, the optimal dosage, the duration of administration of MMC and possible complications, when used during, after and before the surgery. Most studies suggest that increased exposure (dose or duration) of MMC is associated with a lower recurrence, but with higher risks of complications. Twit Text FOAVip Mitomycin C in pterygium treatment ????Int J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=27158622 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27158622 #FOAvip English Wikipedia <ref>{{Cite pmid|27158622}}</ref> Mitomycin C in pterygium treatment #MMPMID27158622 Martins TGdos S; Costa ALFde A; Alves MR; Chammas R; Schor P Int J Ophthalmol 2016[]; 9 (3): 465-8 PMID27158622show ga Pterygium is a benign lesion usually growing from the nasal side of the conjunctiva onto the cornea. Most cases of pterygium does not cause problem or requires specific treatment. The exact cause of pterygium is not clear yet, but some factors are pointed as causes, being the most important the long-term ultraviolet ray exposure. Pterygium surgery is usually considered when there are symptoms that do not respond to conservative treatment. Recurrence is the main complication of the surgery, and much has been done to avoid it. Mitomycin C (MMC) has been used as a fibroblast proliferation inhibitor during the surgery to reduce the chance of recurrence of the pterygium. This review describes the use of MMC as an adjunctive, the optimal dosage, the duration of administration of MMC and possible complications, when used during, after and before the surgery. Most studies suggest that increased exposure (dose or duration) of MMC is associated with a lower recurrence, but with higher risks of complications. äMitomycin C in pterygium treatment (epmc).pdf DeepDyve Pubget Overpricing